Nat Commun:新研究确认35个慢性肾病风险相关基因

2018-11-27 张家伟 中国科学报

英国曼彻斯特大学新发布的一项研究说,研究人员已发现了35个与慢性肾病发病风险相关的基因,未来有望基于这一成果开发出更好的诊断和治疗方法。

英国曼彻斯特大学新发布的一项研究说,研究人员已发现了35个与慢性肾病发病风险相关的基因,未来有望基于这一成果开发出更好的诊断和治疗方法。

鉴于肾病本身涉及很多遗传因素,长期以来学术界对相关遗传机制的不了解限制了这类疾病诊治技术的发展。由曼彻斯特大学学者领衔的国际团队所完成的新科研发现有可能改变这一局面,相关成果已经刊登在英国期刊《自然—通讯》上。

报告主要作者、曼彻斯特大学教授托马谢夫斯基说,团队利用“下一代核糖核酸测序技术”来完成这项研究,“我们希望新发现的肾脏基因中能够找到未来诊断和治疗慢性肾病的有效标靶”。

据研究人员介绍,其中一个名为“mucin-1”的基因引起了他们的注意,这个基因的变异在一些具有家族遗传特性的肾衰竭病患身上已被发现。

研究人员表示,未来如果能够通过基因测试在早期阶段就诊断出肾病风险将更有利于治疗。

原始出处:

Xiaoguang Xu, James M. Eales, Artur Akbarov, et.al. Molecular insights into genome-wide association studies of chronic kidney disease-defining traits. Nature communications 22 November 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2029316, encodeId=ad2e2029316aa, content=<a href='/topic/show?id=9c52e253016' target=_blank style='color:#2F92EE;'>#相关基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72530, encryptionId=9c52e253016, topicName=相关基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Wed Nov 28 12:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883446, encodeId=9d831883446ba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 13 09:16:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087466, encodeId=8da7208e466ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 01 08:16:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353818, encodeId=0c8b353818e6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Nov 27 22:58:28 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353810, encodeId=853935381073, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Nov 27 22:38:26 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2029316, encodeId=ad2e2029316aa, content=<a href='/topic/show?id=9c52e253016' target=_blank style='color:#2F92EE;'>#相关基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72530, encryptionId=9c52e253016, topicName=相关基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Wed Nov 28 12:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883446, encodeId=9d831883446ba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 13 09:16:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087466, encodeId=8da7208e466ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 01 08:16:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353818, encodeId=0c8b353818e6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Nov 27 22:58:28 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353810, encodeId=853935381073, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Nov 27 22:38:26 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2019-10-13 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2029316, encodeId=ad2e2029316aa, content=<a href='/topic/show?id=9c52e253016' target=_blank style='color:#2F92EE;'>#相关基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72530, encryptionId=9c52e253016, topicName=相关基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Wed Nov 28 12:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883446, encodeId=9d831883446ba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 13 09:16:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087466, encodeId=8da7208e466ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 01 08:16:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353818, encodeId=0c8b353818e6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Nov 27 22:58:28 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353810, encodeId=853935381073, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Nov 27 22:38:26 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2019-01-01 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=2029316, encodeId=ad2e2029316aa, content=<a href='/topic/show?id=9c52e253016' target=_blank style='color:#2F92EE;'>#相关基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72530, encryptionId=9c52e253016, topicName=相关基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Wed Nov 28 12:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883446, encodeId=9d831883446ba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 13 09:16:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087466, encodeId=8da7208e466ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 01 08:16:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353818, encodeId=0c8b353818e6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Nov 27 22:58:28 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353810, encodeId=853935381073, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Nov 27 22:38:26 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2018-11-27 医者仁心5538

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2029316, encodeId=ad2e2029316aa, content=<a href='/topic/show?id=9c52e253016' target=_blank style='color:#2F92EE;'>#相关基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72530, encryptionId=9c52e253016, topicName=相关基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Wed Nov 28 12:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883446, encodeId=9d831883446ba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 13 09:16:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087466, encodeId=8da7208e466ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 01 08:16:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353818, encodeId=0c8b353818e6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Nov 27 22:58:28 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353810, encodeId=853935381073, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Nov 27 22:38:26 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2018-11-27 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

Circulation:利拉鲁肽对2型糖尿病合并慢性肾病患者心血管事件的影响

由此可见,将利拉鲁肽加入到标准治疗中可降低T2D合并CKD患者发生重大心血管事件和全因死亡的风险。

roxadustat治疗合并贫血症的慢性肾病患者达到主要研究终点

安斯泰来制药近日宣布,一项针对慢性肾脏病(CKD)患者的III期临床研究(ALPS试验)表明,roxadustat治疗合并有贫血的慢性肾病患者达到主要终点。在ALPS试验中,相比于安慰剂,HIF-PH抑制剂roxadustat表现出显著的前24周血红蛋白(Hb)反应率和第28周至第52周Hb从基线变化的优势。

Radiology:青少年慢性肾病正一步一步地损伤着大脑

本研究旨在通过评价脑血流量(CBF)与临床和行为学指标的相关性探究青少年慢性肾病(CKD)的病理生理变化对脑功能的影响,将结果发表在Radiology上。

Roxadustat在慢性肾病贫血中显示出强大的优势

Roxadustat在中国进行的两项Ⅲ期临床试验(FGCL-4592-808 和 FGCL-4592-806)前期阶段结果积极。 FGCL-4592-808是一项在非透析慢性肾病贫血患者中进行随机、双盲、多中心、安慰剂对照的Ⅲ期临床研究,试验分为Roxadustat受试者组(n=101)和安慰剂对照组(n=50)。每周给药 3 次,共持续 8 周,之后为

卫健委:今年我国器官捐献例数有望突破6000 慢性肾病“广州模式”全国推广

卫健委昨日在广州召开发布会,称今年上半年我国公民逝世后自愿捐献器官已经达到2999例,全年有望突破6000例。中山大学第一附属医院首创的“无缺血”器官移植已完成19例,器官移植或将进入“热移植”时代。而在慢性肾病治疗领域创造的“广州模式”,已在全国基层医疗机构进行了数***的培训。

Circulation:慢性肾病并不是卡格列净的禁忌症!

卡格列净是通过批准的、可用于降低2型糖尿病血糖的药物,对心血管和肾脏具有保护作用。卡格列净对其尚未批准应用的慢性肾病患者(包括估算的肾小球滤过率[eGFR]在30-45mL/min/1.73m2的)是否有益?Brendon L. Neuen等人对此展开研究。CANVAS项目将10 142位eGFR>30mL/min/1.73m2的2型糖尿病患者随机分至卡格列净或安慰剂组。主要结点是心血管原因